Search results

Auna S.A. AUNA and Tenet Healthcare THC are two well-established players in the ambulatory care space. AUNA’s healthcare network provides a range of in-person services through medium to

Global Partners LP (GLP) has been on a downward spiral lately with significant selling pressure. After declining 13% over the past four weeks, the stock looks well positioned for a trend reversal as

Acumen Pharmaceuticals, Inc. (ABOS) has been on a downward spiral lately with significant selling pressure. After declining 33.6% over the past four weeks, the stock looks well positioned for a

DuPont de Nemours Inc. DD is advancing access to safe drinking water in Kenya by deploying its membrane-based treatment solutions in Baringo County, specifically in the remote community of Kampi ya

AbbVie ABBV has built a significant presence in the oncology space. While the majority of the revenues are generated from blood cancer drugs Imbruvica and Venclexta, the company has diversified its

BWX Technologies BWXT and Fluor Corporation FLR are two important players in the nuclear energy space. BWX Technologies focuses on supplying nuclear components, fuel and services mainly to the U.S

Global sportswear leader Nike is set to report its fiscal third-quarter earnings results on Tuesday after the closing bell. A Zacks Rank #3 (Hold), Nike has surpassed the earnings mark in each of

An updated edition of the Feb. 20, 2026, article.The beauty and cosmetics industry continues to stand out as a relatively stable corner of the broader consumer product space, offering a mix of

Investors looking for stocks in the Chemical - Specialty sector might want to consider either H. B. Fuller (FUL) or Novozymes A/S (NVZMY). But which of these two stocks is more attractive to value

Block’s XYZ Cash App is a consumer-focused digital wallet enabling peer-to-peer payments, spending and investing. The platform offers the Cash App Card, a Visa debit card linked to user balances and

ANI Pharmaceuticals ANIP is reshaping its growth profile as specialty therapies take a larger share of the mix. Fiscal 2025 results show accelerating momentum in Rare Disease and Brands, led by

ANI Pharmaceuticals ANIP is setting up 2026 as a year where specialty medicines carry more of the weight. Management expects Rare Disease to represent about 60% of 2026 sales, signaling a continued

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even

Futu Holdings Limited Sponsored ADR (FUTU) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward